Rugged dsRNA for TLR3 Agonist Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional double-stranded ribonucleic acid (dsRNA) therapies face challenges due to susceptibility to hydrolysis and toxicity, limiting their therapeutic efficacy and stability, especially in physiological environments.
Innovation Solution
Development of a 'rugged' dsRNA with a specific molecular structure resistant to denaturation, comprising partially hybridized poly(ribocytidylic acid) and poly(riboinosinic acid strands, which are selectively purified to enhance specificity and reduce adverse effects, acting as a selective agonist for Toll-like receptor 3 (TLR3).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dsRNA is used for therapeutic applications, then it can activate TLR3 and induce interferon synthesis, but it is susceptible to hydrolysis and degradation in physiological environments
Solution Approach 1:
The patent modifies the chemical structure of dsRNA by introducing specific nucleotide sequences and modifications (such as pseudouridine, inosine, or other non-canonical bases) to change the hydrolytic stability parameter. These structural parameter changes reduce susceptibility to hydrolysis while maintaining TLR3 activation capability.
Solution Approach 2:
The patent creates composite nucleic acid structures combining different nucleotide types and modifications within the same dsRNA molecule. This composite structure provides both the functional properties for TLR3 activation and enhanced stability against hydrolysis through the synergistic effects of different nucleotide compositions.
2Object-generated harmful factors
If poly(I):poly(C) is used to induce interferon synthesis, then beneficial immune response is achieved, but toxicity and adverse effects occur
Solution Approach 1:
The patent introduces local modifications at specific positions within the dsRNA sequence, such as incorporating pseudouridine or inosine at particular locations to create regions of controlled instability that promote selective degradation while preserving the core functional sequence for TLR3 binding and interferon induction.
Solution Approach 2:
The patent divides the dsRNA structure into functional segments with different properties - a stable core region for maintaining helical structure and TLR3 interaction, and modified regions that control degradation rate. This segmentation allows independent optimization of stability and biological activity.
3Duration of action of stationary object
If dsRNA is designed to degrade rapidly in nuclease-containing environments, then safety is improved, but half life becomes too short for effective activity
Solution Approach 1:
The patent creates a dynamic degradation profile where the dsRNA maintains structural stability during the critical initial phase for TLR3 activation and interferon induction, then undergoes controlled degradation at a regulated rate. This dynamic behavior ensures both sufficient duration of action and safety through eventual clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The rugged dsRNA exhibits improved stability and bioactivity, with increased specificity and reduced toxicity, effectively activating TLR3 without inducing cytokine storms, making it suitable for therapeutic applications in treating infections and abnormal cell proliferation.
Implementation Method 1
Its 'rugged' molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation)
Implementation Method 2
acting as a selective agonist for activation of Toll-like receptor 3 (TLR3)
Implementation Method 3
which leads to a host defense recruitment sequence, ultimately producing type I interferons
Data Source
Figure 1~2A
Figure 2B~2C
Figure 3A~3B
AI summary
The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its "rugged" molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.